Literature DB >> 16972268

Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation.

Claire Ardouin1, Valerie Voon, Yulia Worbe, Nehman Abouazar, Virginie Czernecki, Hassan Hosseini, Antoine Pelissolo, Elena Moro, Eugénie Lhommée, Anthony E Lang, Yves Agid, Alim-Louis Benabid, Pierre Pollak, Luc Mallet, Paul Krack.   

Abstract

Pathological gambling (PG) related to dopaminergic treatment in Parkinson's disease (PD) is part of a spectrum of behavioral disorders called the dopamine dysregulation syndrome (DDS). We describe a series of PD patients with preoperative active PG due to dopaminergic treatment from a total of 598 patients who have undergone surgery for subthalamic nucleus stimulation for disabling motor fluctuations. The patients had systematic open assessment of behavioral symptoms and standardized assessments of motor symptoms, mood, and apathy. Seven patients (6 men, 1 woman; age, 54 +/- 9 years; levodopa equivalent dose, 1,390 +/- 350 mg/day) had preoperative PG over a mean of 7 years, intolerant to reduction in medication. Six had nonmotor fluctuations and four had other behavioral symptoms consistent with a diagnosis of the DDS. After surgery, motor symptoms improved, allowing for 74% reduction of dopaminergic treatment, below the dosage of gambling onset. In all patients, PG resolved postoperatively after 18 months on average (range, 0-48), although transient worsening occurred in two. Improvement paralleled the time course and degree of reduction in dopaminergic treatment. Nonmotor fluctuations, off period dysphoria, and other symptoms of the DDS improved. Two patients developed persistent apathy. In conclusion, PG and other symptoms of the DDS-associated dopaminergic treatment improved in our patients following surgery. Dopaminergic dysregulation commonly attributed to pulsatile overstimulation of the limbic dopaminergic system may be subject to desensitization on chronic subthalamic stimulation, which has a relative motor selectivity and allows for decrease in dopaminergic treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16972268     DOI: 10.1002/mds.21098

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  61 in total

1.  Zonisamide in managing impulse control disorders in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Cristina Ruiz-Huete; Buenaventura Anciones
Journal:  J Neurol       Date:  2010-05-28       Impact factor: 4.849

2.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

3.  Long-term follow-up of impulse control disorders in Parkinson's disease.

Authors:  Eugenia Mamikonyan; Andrew D Siderowf; John E Duda; Marc N Potenza; Stacy Horn; Matthew B Stern; Daniel Weintraub
Journal:  Mov Disord       Date:  2008-01       Impact factor: 10.338

Review 4.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 5.  Antiparkinsonian medication and pathological gambling.

Authors:  Malcolm Lader
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Deep brain stimulation for Parkinson's disease.

Authors:  Patricia Limousin; Irene Martinez-Torres
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 7.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 8.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 10.  The Subthalamic Nucleus, Limbic Function, and Impulse Control.

Authors:  P Justin Rossi; Aysegul Gunduz; Michael S Okun
Journal:  Neuropsychol Rev       Date:  2015-11-14       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.